Polycystic Kidney Disease Treatment Drugs Market | Contrive Datum Insights

Market Overview:

The Global Polycystic Kidney Disease Treatment Drugs Market Is Projected To Grow At A CAGR Of 7.0% With USD 451 Million By 2022 And 774.9 Million By 2030 During The Forecast Period 2022 To 2030.
{{info}}

Polycystic kidney disease (PKD) is a genetic disease that makes cysts grow in the kidneys and makes them stop working. Two health problems are high blood pressure and kidney failure. PKD is a type of kidney disease that lasts for a long time and is very dangerous. Cysts can make the kidneys bigger, which makes it harder for them to clean the blood of waste.

Chronic kidney disease can be caused by PKD, which can lead to kidney failure or end-stage renal disease. Autosomal dominant PKD and autosomal recessive PKD are the two main types of PKD. These two types of PKD are different because of when they usually start and how they are passed down through families. The PKD Foundation says that more than 600,000 people in the U.S. and 12.4 million people around the world have autosomal dominant polycystic kidney disease. Autosomal recessive polycystic kidney disease is a rare form of the disease that affects only 1 in 20,000 children around the world.

COVID-19 Impact:

In 2020, the spread of COVID-19 had a bad effect on the market of interest in this area. But in 2021, when large-scale vaccination campaigns and the reopening of healthcare units made it easier for people to get back to their polycystic kidney disease treatments, more people came back to these facilities than in 2020. So, the higher demand for new drugs from healthcare facilities will lead to more polycystic kidney disease drugs being made in the area, which will help the market in North America grow significantly over the next few years.

Market Dynamics:

Market Trends:

• Increasing Research Funding

One key trend in the polycystic kidney disease (PKD) drugs market that is helping the market grow is more money going into research. Polycystic kidney disease is a genetic disease that can't be fully cured because there aren't any approved drugs to treat it. Even though the disease is becoming more common, there is a huge unmet need for therapeutics on the market. Because of this, many companies and research centers are looking into making new therapies. But the market faces a problem because most of the vendors and research institutes that do research are small or medium-sized businesses that don't have enough money to do the research well. So, in order to finish their clinical trial research and put the drug on the market, these vendors and organizations need grants from organizations that fund research. In the meantime, there are a number of groups that give money to research, which is helping the market grow.

Driving Factors:

• Development and Testing of Biologics, Drugs, and Medical Devices

The Office of Orphan Products Development at the US Food and Drug Administration (FDA) works to speed up the development and testing of biologics, drugs, and medical devices to treat and diagnose rare diseases. It gives orphan status to biologics and drugs that have been shown to be safe and effective in treating rare diseases. Through the Orphan Products Grants Program (OPGP), it also pays for clinical research to find out how safe and effective these treatments are. In the EU, orphan drugs get help with the protocol and get to be the only ones on the market for ten years. In the US, companies that make orphan drugs can get tax credits for clinical testing, don't have to pay prescription fees (unless the drug is also used for other conditions that aren't orphans), and have market exclusivity for seven years. During this time, generic drugs can't come onto the market, which protects the sales of orphan drugs. These special regulatory designations can help speed up the approval and release of new treatments, which is expected to drive market growth during the forecast period.

• Government Initiatives to Spread Awareness 

By making people aware of polycystic kidney disease through different programs, the government is likely to help the polycystic kidney disease treatment market grow over the next few years. For instance, the Polycystic Kidney Foundation gave about US$40 million to basic and clinical research grants to help find a way to diagnose Polycystic Kidney Disease. This will help the market grow during the time frame predicted.

• The Surge in the Incidence of Autosomal Dominant Polycystic Kidney Diseases (ADPKD)

ADPKD is a rare disease that makes chronic kidney disease and kidney failure more likely. Also, polycystic kidney disease, which is the most common type of chronic kidney disease, makes chronic kidney disease much more common. Since ADPKD is becoming more common, the global polycystic kidney disease drugs market is expected to grow over the next few years. For example, ADPKD affects between 200,000 and 500,000 people in the U.S. and 13,000,000 people around the world, but only about 25% of the population knows about it.

• Increasing Incidences of Kidney Failure 

The polycystic kidney disease market is growing because there are more people who need dialysis or have kidney failure. Polycystic kidney disease can be caused by a number of things, such as a family history of kidney problems, a rare genetic mutation, kidney failure, or being on dialysis. All of these things will increase the polycystic kidney disease market.

Restraints/Challenges:

• Lack of Approved Drugs

One thing that makes it hard for the polycystic kidney disease drugs market to grow is that there aren't enough drugs that have been approved. Unfortunately, there is only one brand-name drug on the market that is approved. Off-label use of antibiotics, drugs for high blood pressure, and nonsteroidal anti-inflammatory drugs (NSAIDs) to treat certain symptoms is a big part of the market right now. Well, because off-label drugs only temporarily relieve symptoms and don't stop the disease from getting worse, patients don't take them as prescribed. Also, there are more and more generic versions of off-label drugs, which pose a big threat to the market. So, the market is likely to lose value because generics are so popular, and the lack of approved therapies is likely to keep slowing the growth of the global polycystic kidney disease drugs market over the next few years.

• High Cost of Treatment and Lack of Trained Professionals are Expected to Hamper the Market Growth.

The main thing holding back treatment for polycystic kidney disease is how expensive it is. Another problem is that there aren't enough trained professionals on the market, even though there is a lot of demand for them. Here are some things that will keep the polycystic kidney disease market from growing.

• Lack of Awareness about Chronic Kidney Disease

Lack of knowledge about chronic kidney disease is likely to slow the growth of the global market for drugs to treat chronic kidney disease. Chronic kidney disease (CKD) could be slowed down, complications could be avoided, and heart problems could be less likely to happen if the disease was found earlier. It has also been shown that getting a person with end-stage renal disease to see a nephrologist early can improve their health. In March 2018, a cross-sectional study was published in BMC Public Health. It found that people in Australia don't know much about chronic kidney disease (CKD), and only half of the people who took part in the study knew that medications can slow the progression of CKD. Also, only 23.4% of the people who took part knew that herbal supplements don't help treat CKD.

Opportunities:

• Increase in the Number of Research and Development Activities       

The market is also growing because there are more research and development projects going on. This will be good for the growth of the market for polycystic kidney disease (PKD). Along with this, more drugs being approved and put on the market will also help the market grow faster.

During the forecast period, the growth of the polycystic kidney disease (PKD) market will also be helped by rising investments in the development of advanced technologies and a rise in the number of emerging markets.

• Technological Innovation

The global polycystic kidney disease treatment market is expected to be driven by technological advances, which will lead to the creation of a wide range of drugs that will help doctors help polycystic kidney disease patients better. For example, in July 2018, Reata Pharmaceuticals, Inc. announced positive phase II data for bardoxolone methyl to treat chronic kidney disease caused by alport syndrome and autosomal dominant polycystic kidney disease.

PKD is common in both rich and poor countries, and it affects people of all races and ethnicities in the same way. The growth of the global polycystic kidney disease treatment market is expected to be helped by programs run by the government to raise awareness about PKD. For example, the PKD Foundation gave more than $40 million to basic and clinical research grants to help find a cure for PKD. In the next few years, however, the growth of the global polycystic kidney disease treatment market is likely to be slowed by the lack of knowledge about the disease in developing countries and the high cost of treatment.

One of the main things that helps the polycystic kidney disease drugs market grow is the number of special regulatory designations. The orphan products grants program (OPGP) pays for clinical research tests to make sure that drugs work and are safe. Organizations like the US FDA and EMA give companies exclusive rights to sell the drugs they make on the market for a certain amount of time. These drug companies also get things like tax breaks for clinical trials and help with protocols.

Strategic Development:

• In July 2022 - Grupo Olmos, a company that provides solutions for renal care, said that it had bought the renal care business of Diaverum, a company that provides renal care in Argentina. The company's line of renal products will get better after it buys the renal business.
• In March 2019 - Aster Hospitals, the largest private healthcare service provider in multiple GCC states, announced that it had started an awareness and screening initiative to help prevent chronic kidney disease (CKD) through education, awareness, and early diagnosis.
• AstraZeneca Plc - Under the unified segment, the company looks for, develops, makes, sells, and markets pharmaceutical products.
• AstraZeneca Plc - The company sells drugs like Forxiga to treat polycystic kidney disease.
• In September 2018 - Reata Pharmaceuticals, Inc., a pharmaceutical company, announced positive results from type 1 diabetic chronic kidney disease (T1D CKD) and IgA nephropathy cohorts of a Phase 2 study called PHOENIX, which looked at bardoxolone methyl (bardoxolone) in patients with rare forms of chronic kidney disease (CKD).
• In September 2019 - Ardelyx, Inc. announced positive results from its phase 3 study, AMPLIFY, for tenapanor in combination with phosphate binders for patients on dialysis with chronic kidney disease (CKD) whose hyperphosphatemia was not controlled by binders alone.

Key Vendors:

Top key vendors are

• Apotex Inc.

Apotex Inc. is a global pharmaceutical company that is proud to be Canadian. It makes high-quality medicines that are affordable for people all over the world. Apotex has almost 8,000 employees around the world who work in manufacturing, research and development, and sales.

• AstraZeneca Plc

Biopharmaceutical company AstraZeneca Plc (AstraZeneca) focuses on finding, making, and selling a wide range of prescription drugs. It makes products for respiratory, cardiovascular, renal, and metabolic diseases, as well as cancer, autoimmune, infectious, and neurological diseases.

• Reddys Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. is a global pharmaceutical company with its main office in Hyderabad, India. They've been around since 1984, and we're committed to making sure people can get affordable and new medicines.

• Galapagos NV

Galapagos NV (Galapagos) is a biotechnology company that finds and makes small-molecule medicines to treat diseases that cause inflammation and scarring. It has the medicine Filgotinib for rheumatoid arthritis (RA).

• Johnson and Johnson

Johnson & Johnson is an American multinational company that has been around since 1886. It makes medical devices, drugs, and packaged goods for consumers.

• Merck and Co. Inc.

Merck & Co., Inc. is a global health care company that sells prescription drugs, vaccines, biologic therapies, animal health products, and personal care products directly and through joint ventures. The Company works in the pharmaceutical, animal health, and consumer care industries.

• Novartis AG

Novartis AG, which goes by the name "Novartis," is a health care company that focuses on finding, developing, making, and selling prescription and generic drugs and eye care products. It has medicines for treating cancer, heart disease, skin problems, neurological diseases, eye and lung diseases, hematologic diseases, solid tumors, immune system problems, and infections, among other things.

• Otsuka Holdings Co. Ltd.

Otsuka Holdings Co Ltd (Otsuka) is a holding company that runs different businesses through its subsidiaries. These businesses include pharmaceuticals, nutraceuticals, consumer goods, and other businesses. Its main goals are to research, make, and sell medicines to treat cancer, heart disease, disorders of the central nervous system, eye diseases, gastrointestinal and respiratory diseases, infectious diseases, skin conditions, and allergies.

• Palladio Biosciences Inc.

Palladio Industries is one of the top companies in the world that makes water-soluble polymers for applications that use a lot of water and a wide range of specialty applications. Palladio is fully backward-integrated and one of the largest producers of bio-acrylamide monomer in the world. It makes this product using an innovative and highly sustainable technology that was developed in-house by using a natural bio-catalyst that was not made with GMOs.

• Reata Pharmaceuticals Inc.

Reata Pharmaceuticals Inc. (Reata) is a biopharmaceutical company that is in the clinical stage. It comes up with new ways to treat diseases that are dangerous and can kill people.

• Regulus Therapeutics Inc.

The biopharmaceutical company Regulus Therapeutics Inc. (Nasdaq:RGLS) is the leader in finding and making new medicines that target microRNAs. Regulus has used its expertise in oligonucleotide drug discovery and development to build a well-balanced microRNA therapeutics pipeline. This pipeline is complemented by a maturing microMarkersSM biomarkers platform and a rich intellectual property estate.

• Sanofi

Sanofi does research on pharmaceutical products, makes them, and sells them. Pharmaceuticals, Consumer Healthcare, and Vaccines are the three business areas it works in.

• Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited is a company that sells medicines. The company creates, makes, and sells both generic and brand-name medicines for people, as well as active pharmaceutical ingredients.

• XORTX Therapeutics Inc

Biopharmaceutical company XORTX Therapeutics Inc. is working on new ways to treat kidney disease that gets worse over time. XORTX has led programs to make treatments for diabetic nephropathy, polycystic kidney disease, and other types of kidney disease that get worse over time.

• Reata Pharmaceuticals

Reata Pharmaceuticals Inc. (Reata) is a biopharmaceutical company that is in the clinical stage. It comes up with new ways to treat diseases that are dangerous and can kill people. Clinical candidates for the company include bardoxolone methyl and omaveloxolone, which target a transcription factor called Nrf2 to improve mitochondrial function, reduce oxidative stress, and stop inflammation.

• Otsuka Holdings

Otsuka Holdings Co Ltd (Otsuka) is a holding company that runs different businesses through its subsidiaries. These businesses include pharmaceuticals, nutraceuticals, consumer goods, and other businesses. Its main goals are to research, make, and sell medicines to treat cancer, heart disease, disorders of the central nervous system, eye diseases, gastrointestinal and respiratory diseases, infectious diseases, skin conditions, and allergies.

Segmentation Analysis:

The market is segmented on the basis of type, drug class, distribution channel, route of administration and region.

By Type Outlook:

Autosomal dominant PKD and autosomal recessive PKD are the two main types of PKD. These two types of PKD are different because of when they usually start and how they are passed down through families. The PKD Foundation says that more than 600,000 people in the U.S. and 12.4 million people around the world have autosomal dominant polycystic kidney disease. Autosomal recessive polycystic kidney disease is a rare form of the disease that affects only 1 in 20,000 children around the world.

In 2021, ADPKD had the largest share of the market for PKD drugs around the world. It will still have the most market shares in 2029. ADPKD is the most common type of PKD, and the number of people who have it is rising all over the world. So, most of the therapeutic candidates in the drug development pipeline are for treating ADPKD. This, along with recent approvals and special drug designations, will help the market segment grow over the next few years.

• Autosomal dominant polycystic kidney disease (ADPKD)
• Autosomal recessive polycystic kidney disease (ARPKD)

By Drug Class:

In terms of value and volume, the Calcium channel blockers segment led the market in 2022, and this trend is expected to continue until the end of the forecast period. Calcium channel blockers (CCBs) are a group of medicines used to treat high blood pressure. They have a wide range of pharmacokinetics and therapeutic effects. Calcium channel blockers relieve the symptoms of many diseases, such as coronary artery disease, high blood pressure, etc., and this is what is driving the growth of the segment.

Because they can help lower high blood pressure, doctors have used calcium channel blockers a lot. One of the most important goals of treatment for high blood pressure is to protect the kidneys from damage. This is especially true given the high rate of chronic kidney disease in the general population (CKD). Recent research has linked CKD to not being able to control blood pressure well and to metabolic syndrome, which is a grouping of other factors that put people at risk for heart disease.

• ACE Inhibitors
• Angiotensin-II Receptor Blockers
• Calcium Channel Blockers
• Beta Blockers
• Erythropoiesis-Stimulating Agents (Esas)
• Diuretics
• Others

By Distribution Channel:

Pain and inflammation management is the first line treatment for autosomal dominant polycystic kidney disease, so this treatment type is expected to have the highest demand around the world. Due to the high rate of prescriptions, the kidney failure management treatment type segment is expected to make up a large part of the global autosomal dominant polycystic kidney disease treatment market. Due to the large number of patients, the hospitals segment is expected to bring in the most money for the global autosomal dominant polycystic kidney disease treatment market.

• Hospitals
• Ambulatory Surgical Centres
• Specialty Clinics 

By Route of Administration:

On the basis of route of administration, the market is segmented into oral, subcutaneous and intravenous.

• Oral
• Subcutaneous
• Intravenous

Regional Insights:

By the end of 2033, the North American polycystic kidney disease drugs market is expected to have the biggest share of the global market. Most of the market's growth can be attributed to a rise in per capita income and a greater awareness of chronic kidney diseases as a result of improvements in the region's medical field. According to information from the World Bank, each person's annual income in the United States went up by USD 69287.5 from USD 63027.7 in 2020 to USD 69287.5 in 2021. Also, the fact that the region has affordable health care policies and does a lot of research and development on drugs is likely to help the market grow in the region. During the forecast period, the global polycystic kidney disease drugs market in the region is also expected to be boosted by a large increase in the medical and health care industries, easy access to drugs, and a sharp rise in dialysis procedures.
{{info2}}

Also, the Asia-Pacific market for drugs to treat polycystic kidney disease is expected to grow a lot by the end of 2033. The market is growing because there are more people with long-term kidney problems and because healthcare is getting better in countries like China, India, and others that are still developing. For example, in the Asia-Pacific region in 2019, there were about 9 million new cases of CKD and almost 783,035 deaths from it. From 1990 to 2019, the number of people with CKD in the region more than doubled, from about 203.8 million to 433.6 million. In addition to this, the increasing number of people who are getting older and the government's efforts to raise awareness about chronic kidney diseases are two other factors that are expected to drive the market growth in the region over the next few years.

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Scope of Report:

Conclusion:

• The market dynamics and upcoming market trends for kidney diseases are carefully examined in this report.
• Detailed analysis is carried out by developing market projections for significant market segments.
• A detailed examination of the variables influencing and limiting market expansion is given.
• This research offers a quantitative analysis of the existing market and projections that help to define the opportunities currently present in the market.
• A detailed assessment of every region is given, revealing the opportunities that are most prominent there.